The relationship between the status of hypertension and lifestyle risk factors in middle-aged and elderly patients with mild cognitive impairment: a case-control study

doi:10.21203/rs.3.rs-1249773/v1

Download PDF

Research Article

The relationship between the status of hypertension and lifestyle risk factors in middle-aged and elderly patients with mild cognitive impairment: a case-control study

https://doi.org/10.21203/rs.3.rs-1249773/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

BACKGROUND

In epidemiological studies, hypertension is related to the difference in the incidence of cognitive impairment, but the evidence is currently inconsistent regarding the association of disease duration, treatment, control, and life risk factors with mild cognitive impairment (MCI) in patients with hypertension.

METHODS

We selected 572 patients with hypertension treated in six medical centers in Nanjing from 2017 to 2020. The cognitive function of participants was assessed using MoCA. Potential risk factors were investigated by a structured questionnaire. Risk factors associated with the conversion of MCI occurring in hypertension were analyzed using multifactorial regression analysis.

RESULTS

MCI was observed in 256 of 572 individuals. MCI was more likely with increasing age (OR=1.15, 95%CI 1.10-1.20), and high education was better at preventing MCI (OR=0.47, 95%CI 0.32-0.71) among baseline clinical characteristics. Risk factors independently associated with MCI were diabetes (OR=2.40, 95%CI 1.53-3.76), Hyperlipidemia (OR=1.49, 95%=1.01-2.16), high salt diet (OR=2.27, 95%CI 1.34-3.84), and physical activity:༞2h/week (OR=0.65, 95%0.44-0.94). Controlling blood pressure to target values helped prevent MCI(OR=0.44, 95%CI 0.30-0.65), and these results were similar when stratified by age.

CONCLUSION

Our results suggest that it is necessary to popularize hypertension knowledge and a healthy lifestyle, and optimize treatment to achieve the goal of preventing cognitive decline in the middle-aged and elderly.

hypertension

mild cognitive impairment

control

risk factors

With the rapid development of China's economy, the aging population in eastern China has also arrived, and the prevalence of hypertension continues to rise. According to the latest survey, the current number of patients with hypertension over 18 years old in China is about 240 million.^[1] It has become one of China’s major public health problems.

Hypertension can cause not only serious complications such as stroke, heart failure, cardiovascular events but also an important risk factor for cognitive impairment.^[2]According to a national epidemiological survey in China, hypertension increases the risk of dementia and MCI by 1.86 and 1.62 times, respectively.^[3] According to its severity, cognitive impairment is often classified into mild cognitive impairment (MCI) and dementia. Evidence has demonstrated that individuals with MCI are at a higher risk of progressing to dementia, particularly in the elderly population.^[4] Cognitive dysfunction can seriously affect the patient's ability to live and socialize while increasing the burden on the patient's economy, family, and society.^[5] In the past few decades, the prevalence of dementia in China has been increasing rapidly.^[3] Therefore, there is an urgent need to identify people at high risk of MCI for early identification and early intervention to prevent these people from progressing to dementia. Moreover, an optimal treatment approach must be developed to prevent the expected social and disease burden.

The current study aims to investigate the cognitive function of hypertensive patients aged between 50 and 75 years old in various regions of Nanjing, China, and their risk factors for developing MCI, to determine whether treatment of hypertension has an effect on cognitive impairment, and to provide a basis for early prevention and delaying the onset of dementia. The findings from this study will provide health professionals with useful information on risk management and measures to reduce cognitive impairment in patients with hypertension.

Study population

Data for this study were collected from patients who, age between 50 and 75 years old, were diagnosed with hypertension in the Affiliated Hospital of Nanjing University of Chinese Medicine, Zhimaying Community Health Service Center, Zhonghuamen Community Health Service Center, Confucius Temple Community Health Service Center, and Chaotiangong Community Health Service Center from May 2017 to October 2020. In this study, patients with non-essential hypertension, severe visual and hearing impairment, Alzheimer's disease, or other causes of dementia, heart failure, and stroke were excluded. The screen flow chart of the study sample is shown in Fig.1. The study was approved by the Ethics Committee of the Affiliated Hospital of Nanjing University of Chinese Medicine (2018NL-080-03), and written informed consent was obtained from the patients or their families.

Data collection

Each participant completed a standardized questionnaire through a face-to-face interview. Data were collected on the participants’ demographic characteristics (age, gender, occupation, education, BMI), medical histories (history of hypertension, diabetes mellitus, white matter hyperintensity, coronary artery disease, hyperlipidemia, and treatment data), and lifestyles (dietary preferences, smoke, drinking alcohol, physical activity, hobbies, sleep duration). The BMI of all patients was classified into four categories according to Chinese adult standards: underweight (BMI < 18.5), normal weight (18.5 ≤ BMI < 24.0), overweight (24.0 ≤ BMI < 28.0), or obesity (BMI ≥ 28.0).^[6]

Neuropsychological and MRI assessment

Trained neurologists evaluated each participant’s cognitive function with the Chinese version of the Montreal Cognitive Assessment (MoCA-Chinese Beijing version) scale, which is a commonly used measurement in China.^[7] For the diagnosis of MCI, the patient should complain of cognitive decline, which was confirmed by others and met the 2011 NIA-AA requirements for the diagnosis of MCI.^[8]It included the following four points: there was altered cognitive function; the cognitive impairment involved one or more cognitive domains; functional independence was maintained; it was not sufficient for a diagnosis of dementia, and the ability to perform daily living was not affected.

The sensitivity of MoCA to detect MCI is higher than that of Mini-Mental Status Exam (MMSE).^[9] Mild cognitive impairment was defined as 18≤MoCA <26.^[10] ^[11]Those with no more than 6-year education add 1 point to the total score.^[12] All subjects underwent MRI on a device with a 1.5-T magnet. MRI was used to estimate the severity of WMH and stroke. All hypertension patients were divided into the MCI group and the non-MCI group.

Statistical analysis

Continuous variables were expressed as the mean ± standard deviation if they followed a normal distribution; otherwise, they were expressed as the median (interquartile range). Categorical variables were expressed as frequencies (percentages). As appropriate one-way analysis of variance or the Kruskal–Wallis test was used to compare continuous variables. Categorical variables were compared using χ² test or Fisher’s exact test, as appropriate. Univariate analysis was performed with the Student's t-test, Mann-Whitney U-test, or Chi-square test. Variables with P<0.05 in univariate analysis were then included in the forward stepwise logistic regression model.

There were some missing values in the data survey of this study, and the following methods were used to deal with the missing values: the questionnaires with vacancy rate ≥ 5% were invalidated; the questionnaires with vacancy rate < 5% were filled with the mean value.

Description of the population

A total of 572 patients (307 males and 265 females) with essential hypertension were included in the present study. The total mean MoCA score was 25.03 ± 3.72 (median 26), and 44.76% (n= 256) of the study participants scored below the recommended cut-off for MCI or dementia (<26 points). The distribution of the MoCA score is shown in Fig.2. Baseline characteristics of the two groups are shown in Table 1. The mean age of the participants was 61.31±4.74 years, ranging from 50 to 75 years, and 49.48% of them (n=283) were workers by occupation. Compared with the non-MCI group, patients in the MCI group were older, and had a lower level of education, higher weight.

Analysis of risk factors for MCI

According to univariate analysis (Table 2), age, education, BMI, cigarette smoking, physical activity, sleep duration, food preferences, WMH, diabetes mellitus, hyperlipidemia, regular medication, controlled hypertensives, and hypertension grade (grade Ⅲ) were significantly different between MCI group and non MCI group (P<0.05). To reduce the effect of confounding factors, we further performed a multivariable analysis with the occurrence of MCI or not as the dependent variable (occurrence =1, not occurrence =0). And the variables with P<0.05 in univariate analysis as the independent variables were included. Logistic stepwise regression the analysis showed that age (OR: 1.15, 95%CI: 1.10-1.20), education (OR: 0.47, 95%CI: 0.32-0.71), physical activity (OR: 0.65, 95%CI: 0.44-0.94), food preferences (OR: 2.27, 95%CI: 1.34-3.84), diabetes mellitus (OR: 2.40, 95%CI: 1.53-3.76), hyperlipidemia (OR: 1.49, 95%CI: 1.01-2.16), controlled hypertensives (OR: 0.44, 95%CI: 0.30-0.65), and hypertension grade (OR: 6.13, 95%CI: 1.47-25.52) were independent risk factors for MCI in hypertensive patients with adjustment for other covariates with P < 0.05 in the univariable analysis.

The probability test outcome variable for predicting MCI was generated based on a multivariable logistic regression data model, and it was plotted as a ROC curve to predict MCI outcomes. The area under the ROC curve was 0.772, which was between 0.7 and 0.9, indicating that the model had a good predictive value. And the P-value <0.001, 95% CI: 0.734-0.810.

Relationship between the current treatment status of hypertension and MCI

Table 3 shows the associations of risk factors between the duration, regular antihypertensive medication, hypertension control, and the prevalence of MCI by gender. After adjusting for age, education, physical activity, food preferences, diabetes mellitus, hyperlipidemia, controlled hypertensives, and hypertension grade. We found that the duration of hypertension and the regular use of anti-hypertensive drugs did not significantly change the prevalence of MCI both in males and female. However, the difference between the controlled hypertensive patients who achieved their treatment goal was significant. In the male and female hypertensive patients, the adjusted OR (95% CI) of having MCI in those participants were 0.47 (0.28-0.79) and 0.40 (0.22-0.73).

Table 4 shows the adjusted variables between the duration, regular antihypertensive medication, and control of hypertension, and the prevalence of MCI by age. We found that the older the group, the lower the percentage of them who were taking antihypertensive medications regularly and having their blood pressure controlled. However, there were no statistically significant differences. In the 58-65 age group (n=351), the adjusted OR (95% CI) of having MCI was 0.40 (0.25-0.66) in those controlled hypertensives compared with those uncontrolled individuals. However, among the regular use of antihypertensive medication patients, there was no difference in the prevalence of MCI between the patients who did not take medication regularly. Also, the differences were not significant between 50–57 years and ⩾65 years.

This study is a population-based case-control study with a strict training process and quality assurance programs. The risk of developing MCI in hypertensive patients in this study appears to be influenced by various factors. And after adjusting for confounding factors, we found that controlling patients' hypertension to target levels (no matter the type of hypertensive drugs used) reduced the incidence of MCI, particularly in the younger elderly population in an urban community in Nanjing China.

Research on hypertension and cognitive impairment first began in the 1960s with the study of pilots.^[13] Until now, there has been controversy about studying the effects of hypertension on cognitive impairment in the middle-aged and elderly population. Several observational studies have found that chronic hypertension, especially high SBP in middle age (40-65 years), was associated with an increased risk of cognitive impairment or dementia in later life.^{[2, 14, 15]} However, studies on the relationship between blood pressure levels and cognitive decline and dementia at older ages have reached inconsistent conclusions. An observational study in Italy has shown that hypertension in the elderly was not related to cognitive impairment.^[16] Some studies have even suggested that higher blood pressure levels are associated with better cognitive function scores.^[17] In the present study, MCI occurred in about 44.8% of hypertensive patients, and we found no significant difference in the prevalence of MCI between 50-57, 58-65, and >65 age groups. However, the prevalence of MCI among adults aged ≥60 years in China was 15.5% in 2020,^[3] significantly lower than that of hypertensive patients in this study. Our findings suggest an effect of hypertension on the onset of MCI in middle-aged and older adults, and grade 3 hypertension was more likely to have cognitive impairment than grade 1 hypertension. But the further expansion of the sample size is needed to confirm the findings.

Currently recognized research concluded that structural changes in the cerebral vasculature secondary to long-term hypertension, with endothelial damage, leading to altered cerebral perfusion was thought to be the main biological pathway linking hypertension to cognitive impairment.^{[18] [19]}Therefore, antihypertensive treatment is crucial. There is controversy about whether lowering blood pressure helps prevent cognitive impairment in patients with hypertension. This year, a cohort study in Brazil showed that effective treatment of hypertension at any age could prevent or slow cognitive decline. ^[20] In 2020, a meta-analysis that included six prospective studies (containing 31,090 participants) showed that receiving antihypertensive therapy reduced the risk of cognitive impairment by 12% and the risk of Alzheimer's disease by 16% compared with not receiving antihypertensive therapy, and this effect was independent of the type of antihypertensive drugs.^[21] Also, there was meta-analyze that held the opposite view. Chang et al. evaluated the association between antihypertensive medication use and the risk of cognitive decline but showed that antihypertensive treatment did not decrease the risk of cognitive decline.^[22]

The present study found that the two key ORs for the prevention of MCI (patients on regular hypertension medication compared with that not on regular hypertension medication and patients with controlled hypertension compared with those uncontrolled hypertension) were similar in the univariate analysis. However, in multivariate regression analysis, we found that the prevalence of MCI was significantly lower in patients with hypertension who reached the treatment target than in those who did not, although they were taking antihypertensive drugs regularly. The results suggest that hypertension treatment has a protective effect on MCI, but treatment targets (blood pressure level) need to be met, and this effect was not statistically significant across different classes of antihypertensive agents (ACEI, ARB, β-blockers, CCB, and else).

In addition, many complex factors may be involved in the poorer cognitive performance of hypertensive patients. Hypertension was always accompanied by other risk factors, such as diabetes and hyperlipidemia. Diabetes can lead to abnormal cerebral angiogenesis and increased capillary density in the central nervous system. This change would accelerate the damage and leakage of blood vessels in the process of neurodegeneration.^[23] Ryuno and his colleagues found that hypertension combined with diabetes was more likely to have future cognitive decline than hypertension or diabetes alone,^[24]which is similar to the results of the current study. Hyperlipidemia can cause chronic inflammation of the nervous system, damage nerve cells and impair the function of vascular endothelial cells, and affect the brain's cognitive function.^[25] The prevalence of MCI in patients with hyperlipidemia was 1.49 times higher than in patients without hyperlipidemia in the current study. But research on the relationship between blood lipids and MCI is still divided, with some researchers suggesting that elevated blood lipids have beneficial effects on cognitive function in the elderly population.^{[26, 27]} Future studies should focus on the interaction of multiple risk factors with a more extended follow-up period.

In terms of personal life, we also identified factors associated with the development of MCI in patients with hypertension in the current study. For instance, education, dietary preferences, and physical exercise. A study by Langa et al. found that as education levels increased, the prevalence of cognitive impairment among those aged 70 and older decreased from 12.2% in 1993 to 8.7% in 2002.^[28] This study suggests that the cognitive reserve generated by early education and cognitive stimulation can prevent MC that the cognitive reserve generated by early education and cognitive stimulation can prevent MCI. Therefore, further strengthening children’s education will help reduce the burden of dementia and cognitive impairment. The salt intake of Chinese residents is one of the highest globally. The average daily intake of salt for adults has been above 10 grams for the past 40 years, more than twice the recommended amount.^[29] Excessive salt intake can directly cause hypertension, which could lead to cognitive decline,^[30] and reduces blood flow to the brain and lead to dementia.^[31] Khater et al. ^[32] confirmed that good dietary status maintains good cognitive health, the Mediterranean dietary pattern has been shown to have a cognitive protective effect, ^[33] but the further research evidence is needed for its use in patients with hypertension. Whether physical exercise affects cognitive impairment in hypertensive patients has not been confirmed by authoritative studies. However, a meta-analysis demonstrated that maintaining physical activity in hypertensive patients helped improve cognitive function scores^[34], and brisk walking for 40 minutes three times per week reduces brain atrophy and improves memory and other cognitive functions.^[35] More research is needed in the future to individualize the type, frequency, and duration of physical exercise.

There are limitations to this study. First, there may be recall bias in the collection of patients data (e.g., disease histories), as each piece of information was self-reported by the patient. To avoid such problems, we asked participants to bring historical medical paperwork and let their relatives join in the conversation if possible. Second, changes in MoCA scores over time were not studied. If differences in MoCA were not related to hypertension, the ability to identify specific risk factors (e.g., treatment for hypertension) would be reduced. Third, specific dietary and blood pressure variances were not collected from participants. The factors may be essential covariates in the analysis of the study. Fourth, the relationship between hypertension and cognitive function is complicated, which the middle-aged and elderly often have an exceptionally high number of risk factors, such as coronary heart disease, depression, and insomnia. And although we adjusted for confounding variables in our analysis, we cannot guarantee the effect of other undetected covariates on the current study results. Fifth, the present study may have been subject to misclassification bias. Some patients may not have taken their antihypertensive medication on the morning of the study because some participants may have been required to fast on the day of the blood test. Their blood pressure may have been elevated on the study day, so the investigators would have misclassified them as patients with irregular medication or uncontrolled hypertension. Finally, Nanjing is a developed area in eastern China and the study results may not be generalizable to less economically developed areas in northwestern China. Further prospective studies with large nationwide sample sizes are needed to explore practical measures to prevent and treat MCI in China's middle-aged and elderly hypertensive population.

This study shows that patients with hypertension who regularly take hypertensive drugs and control their blood pressure to achieve treatment goals have an important role in preventing MCI. And educational level, physical exercise, salty diet, diabetes, and hyperlipidemia are related to cognitive function in hypertensive patients, but it still needs to be confirmed in a larger sample size. Our results suggest that it is necessary to popularize hypertension knowledge and a healthy lifestyle, and optimize treatment to achieve the goal of preventing cognitive decline in the middle-aged and elderly.

MCI: mild cognitive impairment; SD: standard deviation; IQR: interquartile range; BMI: body mass index; WMH: white matter hyperintensities; DOH: duration of hypertension; CCB: calcium Channel Blockers, ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BB: Beta-receptor blocker.

Acknowledge

This study was supported by the National Natural Science Foundation of China (81673759) and the Social Science and Technology Development Program of Jiangsu Province (BE2017769).

Author contributions

XY and CC helped design the study and analyzed the data. XY, TM, JL, JD and HL helped with the data collection and field operations. The manuscript was drafted by XY. All authors contributed to the critical review and final approval of the submitted manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of the Affiliated Hospital of Nanjing University of Chinese Medicine (2018NL-080-03). All of the included patients signed written informed consent forms.

Consent for publication

Not Applicable.

Competing interests

None

WANG Z, CHEN Z, ZHANG L, WANG X, HAO G, ZHANG Z, TIAN SHAOL, DONG Y, ZHENG Y, WANG C, ZHU J. M, WEINTRAUB W S. GAO R. Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015 [J]. Circulation, 2018, 137(22): 2344–56.
IADECOLA C, YAFFE K, BILLER J, BRATZKE L C, HAZZOURI A Z A. Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association [J]. Hypertension, 2016, 68(6): HYP.0000000000000053.
JIA L, DU Y, CHU L, ZHANG Z. QIU Q. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study [J]. The Lancet Public Health. 2020;5(12):e661-e71.
ROBERTS R O, KNOPMAN D S, MIELKE M M, CHA R H, PANKRATZ V S, CHRISTIANSON T, GEDA Y E, BOEVE B F. IVNIK R J, TANGALOS E G. Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal [J]. Neurology. 2016;82(4):317–25.
FRANKISH H. HORTON R. Prevention and management of dementia: a priority for public health [J]. Lancet. 2017;390(10113):2614–5.
ZHOU B. Cooperative Meta-Analysis Group of the Working Group on Obesity. in China Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults—Study on optimal cut-off points of body mass index and waist circumference in Chinese adults [J]. Biomedical & Environmental Sciences, 2002, 15(1): pp. 83–96.
WEN HB, ZHANG Z X, NIU F S, LI L. The application of the Montreal Cognitive Assessment in Beijing, China [J]. Zhonghua nei ke za zhi. Chinese journal of internal medicine. 2008;47(1):36–9.
ALBERT M S JRJC, KNOPMAN D S, MCKHANN G M, SPERLING R A, CARRILLO M C THIESB. PHELPS C H. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [J]. Alzheimers Dementia. 2011;7(3):257–62.
DONG Y H, SHARMA V K, CHAN P L, VENKETASUBRAMANIAN N, TEOH H L, SEET R, CHAN Y H TANICALAS. CHEN C. The Montreal Cognitive Assessment (MoCA) is superior to the Mini-Mental State Examination (MMSE) for the detection of vascular cognitive impairment after acute stroke [J]. J Neurol Sci. 2010;299(1-2):15–8.
NASREDDINE Z S, PHILLIPS N A, BéDIRIAN V, CHARBONNEAU S. CHERTKOW H. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment [J]. J Am Geriatr Soc. 2005;53(4):695–9.
DAVIS D, CREAVIN S T, YIP J, NOEL-STORR A H CULLUMS. Montreal Cognitive Assessment for the diagnosis of Alzheimer's disease and other dementias [J]. cochrane database of systematic reviews; 2015.
PATEL MD, COSHALL C, RUDD A G, WOLFE C D A. Cognitive impairment after stroke: clinical determinants and its associations with long-term stroke outcomes [J]. J Am Geriatr Soc. 2002;50(4):700–6.
LAMB L E. The problem of elevated blood pressure or hypertension in the pilot [J]. The American Journal of Cardiology. 1960;6(1):30–4.
IULITA FLORENCIAM. Treating Hypertension to Prevent Cognitive Decline and Dementia: Re-Opening the Debate [J]. Advances in Experimental Medicine & Biology; 2016. (Chapter 98).
TADIC M, CUSPIDI C. HERING D. Hypertension and cognitive dysfunction in elderly: blood pressure management for this global burden [J]. BMC Cardiovascular Disorders. 2016;16(1):208.
Relationship Between Blood. Pressure and Physical and Cognitive Function in the Oldest Old [J]. J Am Geriatr Soc, 2013, 61(5).
Orthostatic hypotension. hypotension and cognitive status: early comorbid markers of primary dementia? [J]. Dementia Geriatric Cognitive Disorders. 2008;26(3):239–46.
YANG C, DEVISSER A, MARTINEZ J A, POLIAKOV I, ROSALES-HERNANDEZ A, AYER A, GARVEN A, ZAVER S, RINCON N, XU K. RETRACTED: Differential impact of diabetes and hypertension in the brain: Adverse effects in white matter [J]. Neurobiology of Disease. 2011;42(3):446–58.
RODRIGUE K M, RIECK J R, KENNEDY K M, DEVOUS M, DIAZARRASTIA R. PARK D C. Risk Factors for å°¾-Amyloid Deposition in Healthy Aging. Vascular and Genetic Effects [J]; 2013.
MENEZES S, GIATTI L, BRANT L, GRIEP R H, BARRETO SM. Hypertension, Prehypertension, and Hypertension Control: Association With Decline in Cognitive Performance in the ELSA-Brasil Cohort [J]. Hypertension. 2020;77(2):HYPERTENSIONAHA12016080.
JIE D, DAVIS-PLOURDE K L SANAZS, TULLY P J, WANMEI W, CAROLINE P, PASE M P, HIMALI J J, WINDHAM B G MICHAELG. Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies [J]. Lancet Neurol. 2020 Jan;19(1):61–70.
PMHDEV. The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies -. PubMed Health [J]. Centre for Reviews & Dissemination; 2011.
PRAKASH R, JOHNSON M, FAGAN S C ERGULA. Cerebral neovascularization and remodeling patterns in two different models of type 2 diabetes [J]. PLoS One. 2013;8(2):e56264.
RYUNO H, KAMIDE K, GONDO Y, KABAYAMA M, OGURO R, NAKAMA C, YOKOYAMA S, MAEDA-HIRAO S NAGASAWAM, IMAIZUMI Y. Longitudinal association of hypertension and diabetes mellitus with cognitive functioning in a general 70-year-old population: the SONIC study [J]. Hypertension Research, 2017.
FARR S A, YAMADA K A, ALLAN B D, MOHAMMAD A H, LIN X, MILLER N E. BANKS W A, MORLEY J E. Obesity and hypertriglyceridemia produce cognitive impairment [J]. Endocrinology. 2008;149(5):2628–36.
CHEN B, JIN X, GUO R, CHEN Z, HOU X, GAO F, ZHANG Y, ZHENG S, FU C. XUE F. Metabolic Syndrome and Cognitive Performance Among Chinese ≥50 Years: A Cross-Sectional Study with 3988 Participants [J]. Metabolic Syndrome & Related Disorders, 2016: met.2015.0094.
LUO L, YANG M, HAO Q, YUE J. DONG B. Cross-Sectional Study Examining the Association Between Metabolic Syndrome and Cognitive Function Among the Oldest Old [J]. J Am Med Dir Assoc. 2013;14(2):105–8.
LANGA K M, LARSON E B, KARLAWISH J H, CUTLER D M, KABETO M U, KIM S Y. ROSEN A B. Trends in the prevalence and mortality of cognitive impairment in the United States: Is there evidence of a compression of cognitive morbidity? [J]. Alzheimers & Dementia, 2008, 4(2): pp. 134–44.
LI Y, ZHANG P, WU J, MA J. LI X. Twenty-Four-Hour Urinary Sodium and Potassium Excretion and Their Associations With Blood Pressure Among Adults in China: Baseline Survey of Action on Salt China [J]. Hypertension. 2020;76(5):HYPERTENSIONAHA12015238.
FENG JH, LI J, MACGREGOR GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials [J]. BMJ. 2013;346(7903):CD004937.
FARACO G, GARCIA-BONILLA L BREAD, WANG G, RACCHUMI G, BUENDIA I CHANGH, SANTISTEBAN M M, SEGARRA S G, KOIZUMI K. Dietary salt promotes neurovascular and cognitive dysfunction through a gut-initiated TH17 response [J]. Nat Neurosci. 2018;21(2):240.
KHATER MS, ABOUELEZZ N F. Nutritional status in older adults with mild cognitive impairment living in elderly homes in Cairo, Egypt [J]. Journal of Nutrition Health Aging. 2011;15(2):104–8.
CJ A, ATB C. FP D. Cross-sectional and longitudinal associations between adherence to Mediterranean diet with physical performance and cognitive function in older adults: A systematic review and meta-analysis [J]. Ageing Research Reviews, 2021, 70.
KARSSEMEIJER E G A E, AARONSON J A J, BOSSERS W J W, SMITS T T, RIKKERT M G M M O. KESSELS R P C R. Positive effects of combined cognitive and physical exercise training on cognitive function in older adults with mild cognitive impairment or dementia: A meta-analysis [J]. Ageing Research Reviews, 2017: 75–83.
HUTTING K, RODER B. Beneficial effects of physical exercise on neuroplasticity and cognition [J]. Neuroscience Biobehavioral Reviews. 2013;37(9):2243–57.

Table1. Baseline characteristics according to mild cognitive impairment groups

Variable	Total(n=572)	Non-MCI Group (n=316)	MCI Group (n=256)	t/χ²/Z	p-value
Demographic data Age (Mean, SD),year	61.31(4.74)	59.91(4.55)	63.04(4.38)	-8.298	＜0.001
Gender:female,n(%)	265(46.33)	150(47.47)	115(44.92)	0.369	0.544
Education:≥8y,n(%)	208(36.36)	142(44.93)	66(25.78)	22.426	＜0.01
BMI, n(%)				12.235	0.007
Underweight	11(1.92)	2(0.63)	9(3.52)
Normal	331(57.87)	199(62.98)	132(51.56)
Overweight	203(35.49)	103(32.60)	100(39.06)
Obesity	27(4.72)	12(3.80)	15(5.86)
Occupation, n(%)				9.671	0.085
Wokers	283(49.48)	154(48.73)	129(50.39)
Farmers	84(14.69)	46(14.56)	38(14.84)
Teachers and doctors	47(8.22)	34(10.76)	13(5.08)
Civil servants	50(8.74)	31(9.81)	19(7.42)
Business	67(11.71)	33(10.44)	34(13.28)
Unemployed	41(7.17)	18(5.70)	23(8.98)
Living conditions
Cigarette smoking,n (%)	200(34.97)	98(31.01)	102(39.84)	4.850	0.028
Drinking alcohol, n (%)	213(37.24)	110(34.81)	103(40.23)	1.780	0.182
Drink tea, n (%)	241(42.13)	136(43.04)	105(41.02)	0.237	0.626
Physical activity: ＞2h/wk, n (%)	290(50.70)	174(55.06)	116(45.31)	5.380	0.020
Hobbies, n (%)	462(80.77)	256(81.01)	206(80.47)	0.027	0.870
Sleep duration ,n(%) ＜6h/day	273(47.73)	139(43.99)	134(52.34)	3.961	0.047
Food preferences,n(%)				12.035	0.002
Light	140(24.48)	91(28.80)	49(19.14)
General	248(43.36)	126(39.87)	110(42.97)
Salty	149(26.05)	74(23.42)	87(33.98)
Sweet	35(6.12)	25(7.91)	10(3.91)
Medical history
Diabetes ,n(%)	132(23.08)	55(17.41)	77(30.08)	12.769	＜0.001
Hyperlipidemia,n(%)	241(42.13)	119(37.66)	122(47.66)	5.798	0.016
Atherosclerosis ,n(%)	417(72.90)	226(71.52)	191(74.61)	0.684	0.408
WMH ,n(%)	248(43.36)	124(39.24)	124(48.44)	4.872	0.027
DOH:MD(IQR),year	7 (5)	7 (5)	7 (6)	0.550	0.511
Regular antihypertensive medication	380(66.43)	229(72.47)	151(58.94)	11.531	＜0.001
Controlled hypertensives	237(41.43)	156(49.37)	81(31.64)	18.314	＜0.001
Hypertension grade, n(%)				10.159	0.006
Ⅰ	249(43.53)	149(47.15)	100(39.06)
Ⅱ	308(53.85)	164(51.90)	144(56.25)
Ⅲ	15(2.62)	3(0.95)	12(4.69)
Types of antihypertensive drugs, n(%)				8.378	0.079
CCB	166(29.02)	104(32.91)	62(24.22)
ACEI/ARB	257(44.93)	128(40.51)	129(50.39)
ACEI/ARB+CCB	96(16.78)	51(16.14)	45(17.58)
BB	37(6.47)	22(6.96)	15(5.86)
Else	16(2.80)	11(3.48)	5(1.95)

Abbreviation: SD=standard deviation; IQR=interquartile range; BMI= body mass index; WMH=white matter hyperintensities; DOH=duration of hypertension; CCB=calcium Channel Blockers, ACEI=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; BB=Beta-receptor blocker.

Table2. Univariate and stepwise multivariate logic analysis of risk factors for MCI
Variables	univariate		multivariate*
	OR (95%CI)	P-value	OR (95%CI)	P-value
Age	1.17 (1.12-1.22)	＜0.001	1.15 (1.10-1.20)	＜0.001
Gender	0.90 (0.65-1.26)	0.544
Education:≥8y	0.43 (0.30-0.61)	＜0.001	0.47 (0.32-0.71)	＜0.001
BMI
Underweight	6.78 (1.44-31.89)	0.015	3.33 (0.61-18.12)	0.163
Normal	Reference		Reference
Overweight	1.46 (1.03-2.08)	0.034	1.15 (0.72-1.83)	0.555
Obesity	1.88 (0.86-4.15)	0.116	1.16 (0.46-2.94)	0.754
Cigarette smoking	1.47 (1.04-2.08)	0.028	1.42 (0.96-2.11)	0.08
Drinking alcohol	1.26 (0.90-1.77)	0.182
Physical activity:＞2h/wk	0.68 (0.49-0.94)	0.021	0.65 (0.44-0.94)	0.021
Sleep duration ,n(%) ＜6h/day	0.72 (0.51-0.99)	0.047	0.86 (0.59-1.26)	0.453
Food preferences
Light	Reference		Reference
General	1.62 (1.05-2.50)	0.028	1.35 (0.83-2.19)	0.223
Salty	2.18 (1.37-3.48)	0.001	2.27 (1.34-3.84)	0.002
Sweet	0.74 (0.33-1.67)	0.473	0.89 (0.36-2.18)	0.798
WMH	1.46 (1.04-2.03)	0.028	1.08 (0.74-1.58)	0.702
DOH	0.99 (0.96-1.03)	0.744
Diabetes mellitus	2.24 (1.50-3.34)	0.001	2.40 (1.53-3.76)	＜0.001
Hyperlipidemia	1.51 (1.08-2.11)	0.016	1.49 (1.01-2.16)	0.044
Regular antihypertensive medication	0.55 (0.39-0.78)	0.001	0.73 (0.45-1.16)	0.185
Controlled hypertensives	0.48 (0.34-0.67)	＜0.001	0.44 (0.30-0.65)	＜0.001
Hypertension grade
Ⅰ	Reference		Reference
Ⅱ	1.31 (0.93-1.84)	0.119	1.29 (0.88-1.90)	0.193
Ⅲ	5.96 (1.64-21.66)	0.007	6.13 (1.47-25.52)	0.013

*Adjusted with P < 0.05 in the univariable analysis age, education, BMI, physical activity, cigarette smoking, drinking alcohol, sleep duration, food preferences, WMH, diabetes mellitus, hyperlipidemia, regular medication, controlled hypertensives and hypertension grade.

Table 3. Association between the duration, treatment and control of hypertension and the prevalence of MCI by gender
Prevalence of MCI	n,%/ MD(IQR)	Adjusted* OR (95% CI)	P value
Male	307(100)
Duration of hypertension, year	7(5)	0.98 (0.93-1.05)	0.622
Irregular antihypertensive meditation	113(36.8)	Reference
Regular antihypertensive meditation	194(63.2)	1.04 (0.62-1.77)	0.873
Uncontrolled hypertensives	179(58.3)	Reference
Controlled hypertensives	128(41.7)	0.47 (0.28-0.79)	0.005
Female	265(100)
Duration of hypertension	8 (5)	0.96 (0.90-1.02)	0.179
Irregular antihypertensive meditation	79(29.8)	Reference
Regular antihypertensive meditation	186(70.2)	1.01 (0.54-1.92)	0.966
Uncontrolled hypertensives	156(58.9)	Reference
Controlled hypertensives	109(41.1)	0.40 (0.22-0.73)	0.003

*Adjusted for age, education, physical activity, food preferences, diabetes mellitus, hyperlipidemia, controlled hypertensives and hypertension grade.

Table 4. Association between the duration, treatment and control of hypertension and the prevalence of MCI by age
Prevalence of MCI	n,%/ MD(IQR)	Adjusted* OR (95% CI)	P value
50-57 years	117 (100)
Duration of hypertension, years	6 (4)	0.96 (0.74-1.09)	0.516
Irregular antihypertensive meditation	24 (20.5)	Reference
Regular antihypertensive meditation	93 (79.5)	1.82 (0.52-6.30)	0.348
Uncontrolled hypertensives	60 (51.3)	Reference
Controlled hypertensives	57 (48.7)	0.55 (0.20-1.53)	0.253
58-65 years	351 (100)
Duration of hypertension, years	7 (5)	0.96 (0.90-1.01)	0.119
Irregular antihypertensive meditation	126 (35.9)	Reference
Regular antihypertensive meditation	225 (64.1)	0.97 (0.59-1.61)	0.919
Uncontrolled hypertensives	205 (58.4)	Reference
Controlled hypertensives	146 (41.6)	0.40 (0.25-0.66)	＜0.001
＞65 years	104 (100)
Duration of hypertension, years	10 (7)	1.01 (0.93-1.09)	0.807
Irregular antihypertensive meditation	42 (40.4)	Reference
Regular antihypertensive meditation	62 (59.6)	0.78 (0.28-2.16)	0.625
Uncontrolled hypertensives	71 (68.3)	Reference
Controlled hypertensives	33 (31.7)	0.58 (0.21-1.62)	0.3

*Adjusted for age, education, physical activity, food preferences, diabetes mellitus, hyperlipidemia, controlled hypertensives and hypertension grade.

Download PDF

Version 1

posted

You are reading this latest preprint version

The relationship between the status of hypertension and lifestyle risk factors in middle-aged and elderly patients with mild cognitive impairment: a case-control study

Status:

Version 1

Abstract

BACKGROUND

METHODS

RESULTS

CONCLUSION

Figures

Background

Methods

Results

Discussion

Conclusion

Abbreviations

Declarations

References

Tables

Status:

Version 1